Boehringer Ingelheim International Gmbh

Other

Forschungszentrum Juelich Gmbh

Friedrich Goetz

Jiradej Manosroi

Aranya Manosroi

Chatchai Tayapiwatana

Rolf-Guenther Werner

Maria-Regina Kula

Michael Ronald Otto

Guenther Jung

Roderich Suessmuth

Hans-Peter Brockamp

Rolf-Günther Werner

The invention belongs to the field of thrombolysis and of tissue plasminogen activator (tPA) derivative production in prokaryotic cells. The invention relates to methods for the production of a recombinant DNA-derived tPA, a variant thereof or a (Kringle 2 Serine) K2S molecule or a variant thereof in prokaryotic cells, wherein the tPA or K2S or variant is secreted extracellularly as an active and correctly folded protein, and the prokaryotic cell contains and expresses a vector comprising the DNA coding for the tPA or K2S or variant operably linked to the DNA coding for the signal peptide OmpA. The invention further relates to specific K2S derivatives obtainable by the method. The invention further relates to the DNA molecules and the use of the DNA molecules in the methods.

Methods for large scale production of recombinant DNA-derived tPA or K2S molecules

The invention belongs to the field of protein production in prokaryotic cells. The invention relates to methods for the production of recombinant DNA-derived heterologous protein in prokaryotic cells, wherein the heterologous protein is secreted extracellularly as an active and correctly folded protein, and the prokaryotic cell contains and expresses a vector comprising the DNA coding for the heterologous protein operably linked to the DNA coding for the signal peptide OmpA.

Methods for large scale protein production in prokaryotes

The invention belongs to the field of thrombolysis and of tissue plasminogen activator (tPA) derivative production in prokaryotic cells. The invention relates to methods for the production of a recombinant DNA-derived tPA, a variant therof or a (Kringle 2 Serine) K2S molecule or a variant therof in prokaryotic cells, wherein the tPA or K2S or variant is secreted extracellularly as an active and correctly folded protein, and the prokaryotic cell contains and expresses a vector comprising the DNA coding for the tPA or K2S or variant operably linked to the DNA coding for the signal peptide OmpA. The invention further relates to specific K2S derivatives obtainable by the method. The invention further relates to the DNA molecules and the use of the DNA molecules in the methods.

Method for large scale production of recombinant DNA-derived TPA or K2S molecules

The present invention relates to peptides, which are useful in treating Staphylococcus infections. More particularly, the inventive peptides interfere with the regulation of the agr system of Staphylococcus species, especially S. aureus, and thereby block the formation of different virulence factors. The inventive peptides comprise at least the amino acid sequence S V X A S Y F, whereby cyclic structures of that kind of peptides are the most potent blocking reagents.

Lead substances and their use as therapeutics

A fructose-1,6-bisphosphate aldolase with obtained from Staphylococcus carnosus is disclosed. The aldolase has considerably improved stability as compared to aldolase from rabbit muscle, having an inactivation rate of 0.77%/d at 25.degree. C. as compared with 59.3%/d for rabbit muscle aldolase. The aldolase is obtained by culturing Staphylococcus carnosus cells, mechanically disrupting the cell mass, and then working up the product by fractional ammonium sulfate precipitation, pH fractionation and ion exchange chromatography to provide F-1,6-BP aldolase with a specific activity of 25 U/mg in 21% yield. Particularly high yields are obtained by the aqueous 2-phase extraction and obtaining the enzyme from the upper phase by anion exchange chromatography. The aldolase is suitable for synthesis of carbohydrates and derivatives thereof by enzymatic reaction of aldehydes with DHAP.

Growing community of inventors

Tuebingen, Germany

Friedrich Goetz